INDP vs. NRSN, GLTO, APM, VINC, AVTX, KALA, BIVI, TLPH, ORGS, and SLGL
Should you be buying Indaptus Therapeutics stock or one of its competitors? The main competitors of Indaptus Therapeutics include NeuroSense Therapeutics (NRSN), Galecto (GLTO), Aptorum Group (APM), Vincerx Pharma (VINC), Avalo Therapeutics (AVTX), KALA BIO (KALA), BioVie (BIVI), Talphera (TLPH), Orgenesis (ORGS), and Sol-Gel Technologies (SLGL). These companies are all part of the "pharmaceutical preparations" industry.
NeuroSense Therapeutics (NASDAQ:NRSN) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, community ranking, media sentiment, institutional ownership, dividends, valuation and risk.
Indaptus Therapeutics received 8 more outperform votes than NeuroSense Therapeutics when rated by MarketBeat users. However, 100.00% of users gave NeuroSense Therapeutics an outperform vote while only 83.33% of users gave Indaptus Therapeutics an outperform vote.
Indaptus Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 476.92%. Given NeuroSense Therapeutics' higher probable upside, analysts plainly believe Indaptus Therapeutics is more favorable than NeuroSense Therapeutics.
1.0% of NeuroSense Therapeutics shares are held by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are held by institutional investors. 27.4% of NeuroSense Therapeutics shares are held by insiders. Comparatively, 27.1% of Indaptus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.
NeuroSense Therapeutics' return on equity of -91.78% beat Indaptus Therapeutics' return on equity.
In the previous week, NeuroSense Therapeutics had 3 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 5 mentions for NeuroSense Therapeutics and 2 mentions for Indaptus Therapeutics. NeuroSense Therapeutics' average media sentiment score of 0.63 beat Indaptus Therapeutics' score of 0.36 indicating that Indaptus Therapeutics is being referred to more favorably in the news media.
NeuroSense Therapeutics has a beta of 1.73, meaning that its stock price is 73% more volatile than the S&P 500. Comparatively, Indaptus Therapeutics has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500.
Summary
Indaptus Therapeutics beats NeuroSense Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Indaptus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for INDP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Indaptus Therapeutics Competitors List
Related Companies and Tools
